{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:15:44Z","timestamp":1790320544976,"version":"4.1.0"},"reference-count":187,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1143412"],"award-info":[{"award-number":["GNT1143412"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01946","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T04:17:38Z","timestamp":1536553058000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":75,"title":["Treating Influenza Infection, From Now and Into the Future"],"prefix":"10.3389","volume":"9","author":[{"given":"Sophia","family":"Davidson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S1473-3099(02)00366-3","article-title":"Influenza\u2013WHO cares","volume":"2","author":"Stohr","year":"2002","journal-title":"Lancet Infect Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1016\/j.vaccine.2005.07.046","article-title":"A review of vaccine research and development: human acute respiratory infections","volume":"23","author":"Girard","year":"2005","journal-title":"Vaccine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.virusres.2011.09.022","article-title":"Immune responses to influenza virus infection","volume":"162","author":"Kreijtz","year":"2011","journal-title":"Virus Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e1003657","DOI":"10.1371\/journal.ppat.1003657","article-title":"New world bats harbor diverse influenza A viruses","volume":"9","author":"Tong","year":"2013","journal-title":"PLoS Pathog."},{"key":"B5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1126\/science.1122438","article-title":"Global patterns of influenza a virus in wild birds","volume":"312","author":"Olsen","year":"2006","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3389\/fimmu.2016.00060","article-title":"Avian influenza viruses, inflammation, and CD8(+) T cell immunity","volume":"7","author":"Wang","year":"2016","journal-title":"Front Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3201\/eid1312.070615","article-title":"Swine influenza (H3N2) infection in a child and possible community transmission, Canada","volume":"13","author":"Robinson","year":"2007","journal-title":"Emerg Infect Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e1002082","DOI":"10.1371\/journal.pbio.1002082","article-title":"Estimating the life course of influenza A(H3N2) antibody responses from cross-sectional data","volume":"13","author":"Kucharski","year":"2015","journal-title":"PLoS Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1126\/science.1178258","article-title":"Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift","volume":"326","author":"Hensley","year":"2009","journal-title":"Science"},{"key":"B10","first-page":"86","article-title":"The origin and virulence of the 1918 \u201cSpanish\u201d influenza virus","volume":"150","author":"Taubenberger","year":"2006","journal-title":"Proc Am Philos Soc."},{"key":"B11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1473-3099(13)70286-X","article-title":"Pathogenesis of influenza-induced acute respiratory distress syndrome","volume":"14","author":"Short","year":"2014","journal-title":"Lancet Infect Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1172\/JCI1355","article-title":"Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense","volume":"101","author":"Hayden","year":"1998","journal-title":"J Clin Invest."},{"key":"B13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/jmv.1045","article-title":"Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses","volume":"64","author":"Kaiser","year":"2001","journal-title":"J Med Virol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0140-6736(04)15595-5","article-title":"Re-emergence of fatal human influenza A subtype H5N1 disease","volume":"363","author":"Peiris","year":"2004","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/nm1477","article-title":"Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia","volume":"12","author":"De Jong","year":"2006","journal-title":"Nat Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1001\/jama.2009.1583","article-title":"Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California","volume":"302","author":"Louie","year":"2009","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e13099","DOI":"10.1371\/journal.pone.0013099","article-title":"Role of host immune response and viral load in the differential outcome of pandemic H1N1 (2009) influenza virus infection in Indian patients","volume":"5","author":"Arankalle","year":"2010","journal-title":"PLoS ONE"},{"key":"B18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrmicro3231","article-title":"The co-pathogenesis of influenza viruses with bacteria in the lung","volume":"12","author":"Mccullers","year":"2014","journal-title":"Nat Rev Microbiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1172\/JCI35412","article-title":"Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice","volume":"119","author":"Shahangian","year":"2009","journal-title":"J Clin Invest."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.15252\/embr.201540473","article-title":"TRAIL+ monocytes and monocyte-related cells cause lung damage and thereby increase susceptibility to influenza-Streptococcus pneumoniae coinfection","volume":"16","author":"Ellis","year":"2015","journal-title":"EMBO Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fmicb.2018.00123","article-title":"Universal vaccines and vaccine platforms to protect against influenza viruses in humans and agriculture","volume":"9","author":"Rajao","year":"2018","journal-title":"Front Microbiol."},{"key":"B22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.32607\/20758251-2009-1-2-26-32","article-title":"Influenza virus neuraminidase: structure and function","volume":"1","author":"Shtyrya","year":"2009","journal-title":"Acta Naturae"},{"key":"B23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/1743-422X-10-321","article-title":"Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase","volume":"10","author":"Cohen","year":"2013","journal-title":"Virol J."},{"key":"B24","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/JVI.67.6.2972-2980.1993","article-title":"Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase","volume":"67","author":"Colman","year":"1993","journal-title":"J Virol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2147\/IDR.S36601","article-title":"Influenza treatment and prophylaxis with neuraminidase inhibitors: a review","volume":"6","author":"Kamali","year":"2013","journal-title":"Infect Drug Resist."},{"key":"B26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ccm.2016.11.008","article-title":"Antiviral treatments","volume":"38","author":"Ison","year":"2017","journal-title":"Clin Chest Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/00001432-199812000-00013","article-title":"In-vitro and in-vivo efficacy of influenza neuraminidase inhibitors","volume":"11","author":"Mendel","year":"1998","journal-title":"Curr Opin Infect Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1001\/jama.2009.294","article-title":"Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States","volume":"301","author":"Dharan","year":"2009","journal-title":"JAMA"},{"key":"B29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.antiviral.2009.03.003","article-title":"Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa","volume":"83","author":"Hurt","year":"","journal-title":"Antiviral Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.2165\/11531450-000000000-00000","article-title":"Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses","volume":"69","author":"Hurt","year":"","journal-title":"Drugs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3201\/eid1504.181280","article-title":"Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season","volume":"15","author":"Meijer","year":"2009","journal-title":"Emerg Infect Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/nature06956","article-title":"Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants","volume":"453","author":"Collins","year":"2008","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00726-008-0201-z","article-title":"Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation","volume":"37","author":"Malaisree","year":"2009","journal-title":"Amino Acids"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1128\/AAC.46.12.3809-3816.2002","article-title":"Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir","volume":"46","author":"Wang","year":"2002","journal-title":"Antimicrob Agents Chemother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1056\/NEJMp0900648","article-title":"Global transmission of oseltamivir-resistant influenza","volume":"360","author":"Moscona","year":"2009","journal-title":"N Engl J Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jama.2009.324","article-title":"The evolution of influenza resistance and treatment","volume":"301","author":"Weinstock","year":"2009","journal-title":"JAMA"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1056\/NEJMc1111078","article-title":"Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza","volume":"365","author":"Hurt","year":"2011","journal-title":"N Engl J Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.antiviral.2012.12.013","article-title":"Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir","volume":"97","author":"Wang","year":"2013","journal-title":"Antiviral Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/fampra\/cms059","article-title":"Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials","volume":"30","author":"Ebell","year":"2013","journal-title":"Fam Pract."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e60348","DOI":"10.1371\/journal.pone.0060348","article-title":"The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews","volume":"8","author":"Michiels","year":"2013","journal-title":"PLoS ONE"},{"key":"B41","doi-asserted-by":"publisher","first-page":"g2545","DOI":"10.1136\/bmj.g2545","article-title":"Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments","volume":"348","author":"Jefferson","year":"2014","journal-title":"BMJ"},{"key":"B42","doi-asserted-by":"publisher","first-page":"CD008965","DOI":"10.1002\/14651858.CD008965.pub3","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children","author":"Jefferson","year":"2014","journal-title":"Cochrane Database Syst Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e113633","DOI":"10.1371\/journal.pone.0113633","article-title":"Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies","volume":"9","author":"Okoli","year":"2014","journal-title":"PLoS ONE"},{"key":"B44","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.biochem.69.1.531","article-title":"Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin","volume":"69","author":"Skehel","year":"2000","journal-title":"Annu Rev Biochem."},{"key":"B45","doi-asserted-by":"publisher","first-page":"17736","DOI":"10.1073\/pnas.0807142105","article-title":"Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion","volume":"105","author":"Russell","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B46","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/9299","article-title":"A complex of influenza hemagglutinin with a neutralizing antibody that binds outside the virus receptor binding site","volume":"6","author":"Fleury","year":"1999","journal-title":"Nat Struct Biol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2567.2006.02421.x","article-title":"Variation and infectivity neutralization in influenza","volume":"119","author":"Knossow","year":"2006","journal-title":"Immunology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"9430","DOI":"10.1073\/pnas.1510816112","article-title":"Structures of complexes formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody","volume":"112","author":"Xiong","year":"2015","journal-title":"Proc Natl Acad Sci USA."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e1001211","DOI":"10.1371\/journal.ppat.1001211","article-title":"Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain","volume":"6","author":"Das","year":"2010","journal-title":"PLoS Pathog."},{"key":"B50","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1126\/scitranslmed.3005996","article-title":"Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses","volume":"5","author":"Medina","year":"2013","journal-title":"Sci Transl Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.1205669","article-title":"A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nm.3443","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo","volume":"20","author":"Dilillo","year":"2014","journal-title":"Nat Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1172\/JCI84428","article-title":"Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection","volume":"126","author":"Dilillo","year":"2016","journal-title":"J Clin Invest."},{"key":"B54","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.chom.2014.04.009","article-title":"Broadly neutralizing influenza hemagglutinin stem-specific antibody CR8020 targets residues that are prone to escape due to host selection pressure","volume":"15","author":"Tharakaraman","year":"2014","journal-title":"Cell Host Microbe"},{"key":"B55","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1080\/19420862.2016.1167294","article-title":"Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A","volume":"8","author":"Gupta","year":"2016","journal-title":"MAbs"},{"key":"B56","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2016.05.073","article-title":"Structure and function analysis of an antibody recognizing all influenza A subtypes","volume":"166","author":"Kallewaard","year":"2016","journal-title":"Cell"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1128\/AAC.02457-15","article-title":"The hemagglutinin stem-binding monoclonal antibody VIS410 controls influenza virus-induced acute respiratory distress syndrome","volume":"60","author":"Baranovich","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e01154","DOI":"10.1128\/AAC.01154-17","article-title":"Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza A virus challenge model","volume":"61","author":"Mcbride","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"B59","doi-asserted-by":"publisher","first-page":"S519","DOI":"10.1093\/ofid\/ofx163.1352","article-title":"A phase 2a study to evaluate the safety of MEDI8852 in outpatient adults with acute, uncomplicated influenza A","volume":"4","author":"Omar Ali","year":"2017","journal-title":"Open Forum Infect Dis."},{"key":"B60","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ebiom.2016.02.021","article-title":"Safety and upper respiratory pharmacokinetics of the hemagglutinin stalk-binding antibody VIS410 support treatment and prophylaxis based on population modeling of seasonal influenza A outbreaks","volume":"5","author":"Wollacott","year":"2016","journal-title":"EBioMedicine"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1128\/AAC.02440-12","article-title":"Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies","volume":"57","author":"Rayner","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"B62","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/B978-0-12-407698-3.00004-1","article-title":"Influenza virus transcription and replication","volume":"87","author":"Martin-Benito","year":"2013","journal-title":"Adv Virus Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.antiviral.2016.07.008","article-title":"JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses","volume":"133","author":"Fu","year":"2016","journal-title":"Antiviral Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.antiviral.2016.10.009","article-title":"Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice","volume":"136","author":"Smee","year":"2016","journal-title":"Antiviral Res."},{"key":"B65","volume-title":"VX-787 Showed Significant Antiviral Activity and Reduced the Severity and Duration of Influenza Symptoms in Phase 2 Challenge Study.","year":"2016"},{"key":"B66","doi-asserted-by":"publisher","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J Virol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob Agents Chemother."},{"key":"B69","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1128\/AAC.01051-06","article-title":"Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice","volume":"51","author":"Sidwell","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"B70","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1073\/pnas.0909603107","article-title":"T-705 (favipiravir) activity against lethal H5N1 influenza A viruses","volume":"107","author":"Kiso","year":"2010","journal-title":"Proc Natl Acad Sci USA."},{"key":"B71","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob Agents Chemother."},{"key":"B73","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1038\/ncomms5794","article-title":"Generation and characterization of influenza A viruses with altered polymerase fidelity","volume":"5","author":"Cheung","year":"2014","journal-title":"Nat Commun."},{"key":"B74","doi-asserted-by":"publisher","first-page":"7989","DOI":"10.1128\/JVI.74.17.7989-7996.2000","article-title":"Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein","volume":"74","author":"Talon","year":"2000","journal-title":"J Virol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"11566","DOI":"10.1128\/JVI.74.24.11566-11573.2000","article-title":"Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha\/beta interferon","volume":"74","author":"Wang","year":"2000","journal-title":"J Virol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"11166","DOI":"10.1128\/JVI.76.21.11166-11171.2002","article-title":"The influenza A virus NS1 protein inhibits activation of Jun N-terminal kinase and AP-1 transcription factors","volume":"76","author":"Ludwig","year":"2002","journal-title":"J Virol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"13257","DOI":"10.1128\/JVI.77.24.13257-13266.2003","article-title":"A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice","volume":"77","author":"Donelan","year":"2003","journal-title":"J Virol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1126\/science.1132998","article-title":"RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates","volume":"314","author":"Pichlmair","year":"2006","journal-title":"Science"},{"key":"B79","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/nature05732","article-title":"TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity","volume":"446","author":"Gack","year":"2007","journal-title":"Nature"},{"key":"B80","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1165\/rcmb.2006-0283RC","article-title":"NS1 protein of influenza A virus inhibits the function of intracytoplasmic pathogen sensor, RIG-I","volume":"36","author":"Guo","year":"2007","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1128\/JVI.01265-06","article-title":"Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus","volume":"81","author":"Mibayashi","year":"2007","journal-title":"J Virol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/j.1462-5822.2006.00841.x","article-title":"IFNbeta induction by influenza A virus is mediated by RIG-I which is regulated by the viral NS1 protein","volume":"9","author":"Opitz","year":"2007","journal-title":"Cell Microbiol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"12761","DOI":"10.1128\/JVI.00701-10","article-title":"Glycine 184 in nonstructural protein NS1 determines the virulence of influenza A virus strain PR8 without affecting the host interferon response","volume":"84","author":"Steidle","year":"2010","journal-title":"J Virol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1006\/viro.1998.9508","article-title":"Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems","volume":"252","author":"Garcia-Sastre","year":"1998","journal-title":"Virology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nature01783","article-title":"Viral infection switches non-plasmacytoid dendritic cells into high interferon producers","volume":"424","author":"Diebold","year":"2003","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","first-page":"e1000151","DOI":"10.1371\/journal.ppat.1000151","article-title":"Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses","volume":"4","author":"Mordstein","year":"2008","journal-title":"PLoS Pathog."},{"key":"B87","doi-asserted-by":"publisher","first-page":"6925","DOI":"10.1128\/JVI.00283-13","article-title":"Visualizing the beta interferon response in mice during infection with influenza A viruses expressing or lacking nonstructural protein 1","volume":"87","author":"Kallfass","year":"2013","journal-title":"J Virol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1099\/vir.0.025015-0","article-title":"Novel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner","volume":"92","author":"Walkiewicz","year":"2011","journal-title":"J Gen Virol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.bmc.2011.10.026","article-title":"Design, synthesis, and evaluation of novel small molecule inhibitors of the influenza virus protein NS1","volume":"20","author":"Jablonski","year":"2012","journal-title":"Bioorg Med Chem."},{"key":"B90","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00705-015-2668-8","article-title":"The c-Jun N-terminal kinase (JNK) is involved in H5N1 influenza A virus RNA and protein synthesis","volume":"161","author":"Zhang","year":"2016","journal-title":"Arch Virol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1517\/17460441.2015.1019859","article-title":"Learning from structure-based drug design and new antivirals targeting the ribonucleoprotein complex for the treatment of influenza","volume":"10","author":"Monod","year":"2015","journal-title":"Expert Opin Drug Discov."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1056\/NEJMra052211","article-title":"Avian influenza A (H5N1) infection in humans","volume":"353","author":"Beigel","year":"2005","journal-title":"N Engl J Med."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019872","article-title":"Severe and persistent depletion of circulating plasmacytoid dendritic cells in patients with 2009 pandemic H1N1 infection","author":"Lichtner","year":"2011","journal-title":"PLoS ONE"},{"key":"B94","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2165\/00003495-199142050-00003","article-title":"The use of interferon-alpha in virus infections","volume":"42","author":"Finter","year":"1991","journal-title":"Drugs"},{"key":"B95","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1086\/314938","article-title":"Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment","volume":"180","author":"Fritz","year":"1999","journal-title":"J Infect Dis."},{"key":"B96","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1002\/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L","article-title":"Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology","volume":"31","author":"Hussell","year":"2001","journal-title":"Eur J Immunol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S1471-4892(01)00083-2","article-title":"Recent advances in the treatment of rhinovirus infections","volume":"1","author":"Mckinlay","year":"2001","journal-title":"Curr Opin Pharmacol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1292\/jvms.71.611","article-title":"Association of tumor necrosis factor-alpha with fever and pulmonary lesion score in pigs experimentally infected with swine influenza virus subtype H1N2","volume":"71","author":"Kim","year":"2009","journal-title":"J Vet Med Sci."},{"key":"B99","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1177\/1756283X10366368","article-title":"Anti-tumor necrosis factor therapy and influenza: keeping it in perspective","volume":"3","author":"Shale","year":"2010","journal-title":"Therap Adv Gastroenterol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1073\/pnas.1321748111","article-title":"Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection","volume":"111","author":"Wang","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.15252\/emmm.201606413","article-title":"IFNlambda is a potent anti-influenza therapeutic without the inflammatory side effects of IFNalpha treatment","volume":"8","author":"Davidson","year":"2016","journal-title":"EMBO Mol Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1042\/BSR20100040","article-title":"New developments on the TNFalpha-mediated signalling pathways","volume":"31","author":"Sethu","year":"2011","journal-title":"Biosci Rep."},{"key":"B103","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1128\/JVI.80.7.3515-3522.2006","article-title":"Tumor necrosis factor alpha enhances influenza A virus-induced expression of antiviral cytokines by activating RIG-I gene expression","volume":"80","author":"Matikainen","year":"2006","journal-title":"J Virol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1128\/JVI.02336-06","article-title":"Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice","volume":"81","author":"Szretter","year":"2007","journal-title":"J Virol."},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1186\/cc13171","article-title":"Inhibition of the inflammatory cytokine tumor necrosis factor-alpha with etanercept provides protection against lethal H1N1 influenza infection in mice","author":"Shi","year":"2013","journal-title":"Crit Care"},{"key":"B106","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1471-2474-13-158","article-title":"Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study","volume":"13","author":"Blumentals","year":"2012","journal-title":"BMC Musculoskelet Disord."},{"key":"B107","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1016\/j.ajpath.2011.09.003","article-title":"Negative regulation of lung inflammation and immunopathology by TNF-alpha during acute influenza infection","volume":"179","author":"Damjanovic","year":"2011","journal-title":"Am J Pathol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"5839","DOI":"10.4049\/jimmunol.1302729","article-title":"Soluble, but not transmembrane, TNF-alpha is required during influenza infection to limit the magnitude of immune responses and the extent of immunopathology","volume":"192","author":"Deberge","year":"2014","journal-title":"J Immunol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.bbrc.2007.02.019","article-title":"Protection from lethal influenza virus challenge by oral type 1 interferon","volume":"355","author":"Beilharz","year":"2007","journal-title":"Biochem Biophys Res Commun."},{"key":"B110","doi-asserted-by":"publisher","first-page":"10818","DOI":"10.1128\/JVI.01116-07","article-title":"The Mx1 gene protects mice against the pandemic 1918 and highly lethal human H5N1 influenza viruses","volume":"81","author":"Tumpey","year":"2007","journal-title":"J Virol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1128\/JVI.02453-08","article-title":"Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets","volume":"83","author":"Kugel","year":"2009","journal-title":"J Virol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1128\/JVI.02174-08","article-title":"Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding","volume":"83","author":"Van Hoeven","year":"2009","journal-title":"J Virol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"e29255","DOI":"10.1371\/journal.pone.0029255","article-title":"Exogenous IFN-alpha administration reduces influenza A virus replication in the lower respiratory tract of rhesus macaques","volume":"6","author":"Matzinger","year":"2011","journal-title":"PLoS ONE"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1128\/JVI.06156-11","article-title":"Molecular signatures associated with Mx1-mediated resistance to highly pathogenic influenza virus infection: mechanisms of survival","volume":"86","author":"Cilloniz","year":"2012","journal-title":"J Virol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1038\/ncomms4864","article-title":"Pathogenic potential of interferon alphabeta in acute influenza infection","volume":"5","author":"Davidson","year":"2014","journal-title":"Nat Commun."},{"key":"B116","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1128\/JVI.74.9.3996-4003.2000","article-title":"The role of alpha\/beta and gamma interferons in development of immunity to influenza A virus in mice","volume":"74","author":"Price","year":"2000","journal-title":"J Virol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1128\/JVI.01718-06","article-title":"Protective role of beta interferon in host defense against influenza A virus","volume":"81","author":"Koerner","year":"2007","journal-title":"J Virol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.1128\/JVI.02144-08","article-title":"Early control of H5N1 influenza virus replication by the type I interferon response in mice","volume":"83","author":"Szretter","year":"2009","journal-title":"J Virol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrd2356","article-title":"Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules","volume":"8","author":"Marsolais","year":"2009","journal-title":"Nat Rev Drug Discov."},{"key":"B120","doi-asserted-by":"publisher","first-page":"12018","DOI":"10.1073\/pnas.1107024108","article-title":"Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci USA."},{"key":"B121","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.cell.2011.08.015","article-title":"Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection","volume":"146","author":"Teijaro","year":"2011","journal-title":"Cell"},{"key":"B122","doi-asserted-by":"publisher","first-page":"e58033","DOI":"10.1371\/journal.pone.0058033","article-title":"Three phases of CD8 T cell response in the lung following H1N1 influenza infection and sphingosine 1 phosphate agonist therapy","volume":"8","author":"Matheu","year":"2013","journal-title":"PLoS ONE"},{"key":"B123","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1073\/pnas.1400593111","article-title":"Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection","volume":"111","author":"Teijaro","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1073\/pnas.1525356113","article-title":"S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-alpha autoamplification","volume":"113","author":"Teijaro","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B125","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"6878","DOI":"10.4049\/jimmunol.175.10.6878","article-title":"Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection","volume":"175","author":"Carey","year":"2005","journal-title":"J Immunol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.immuni.2014.02.013","article-title":"Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages","volume":"40","author":"Coulombe","year":"2014","journal-title":"Immunity"},{"key":"B128","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1086\/590499","article-title":"Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection","volume":"198","author":"Lee","year":"2008","journal-title":"J Infect Dis."},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011610","article-title":"Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice","author":"Carey","year":"2010","journal-title":"PLoS ONE"},{"key":"B130","doi-asserted-by":"publisher","first-page":"8091","DOI":"10.1073\/pnas.0711942105","article-title":"Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A\/H5N1 virus","volume":"105","author":"Zheng","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B131","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1185\/030079902125001335","article-title":"The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity","volume":"18","author":"Tacconelli","year":"2002","journal-title":"Curr Med Res Opin."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1086\/606060","article-title":"Salicylates and pandemic influenza mortality, 1918-1919 pharmacology, pathology, and historic evidence","volume":"49","author":"Starko","year":"2009","journal-title":"Clin Infect Dis."},{"key":"B133","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1258\/jrsm.2010.090441","article-title":"The effect on mortality of antipyretics in the treatment of influenza infection: systematic review and meta-analysis","volume":"103","author":"Eyers","year":"2010","journal-title":"J R Soc Med."},{"key":"B134","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1086\/505116","article-title":"Pandemic influenza: a potential role for statins in treatment and prophylaxis","volume":"43","author":"Fedson","year":"2006","journal-title":"Clin Infect Dis."},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.2174\/1570161116666180723120608","article-title":"Pleotropic Effects of Statins: untapped potential for statin pharmacotherapy","author":"Mohammad","year":"2018","journal-title":"Curr Vasc Pharmacol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1161\/circ.116.suppl_16.II_7","article-title":"Statins block influenza infection by down-regulating rho\/rho kinase pathway","volume":"116","author":"Haidari","year":"2007","journal-title":"Circulation"},{"key":"B137","doi-asserted-by":"publisher","first-page":"872370","DOI":"10.1155\/2014\/872370","article-title":"Mechanisms of action and efficacy of statins against influenza","volume":"2014","author":"Mehrbod","year":"2014","journal-title":"Biomed Res Int."},{"key":"B138","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4149\/av_2012_04_353","article-title":"Statins reduce the expression of proinflammatory cytokines in influenza A virus infected CrFK cells","volume":"56","author":"Mehrbod","year":"2012","journal-title":"Acta Virol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1183\/09031936.00050612","article-title":"Simvastatin suppresses RANTES-mediated neutrophilia in polyinosinic-polycytidylic acid-induced pneumonia","volume":"41","author":"Lee","year":"2013","journal-title":"Eur Respir J."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.mehy.2011.09.001","article-title":"Triple combinations of neuraminidase inhibitors, statins and fibrates benefit the survival of patients with lethal avian influenza pandemic","volume":"77","author":"An","year":"2011","journal-title":"Med Hypotheses"},{"key":"B141","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ejps.2009.07.004","article-title":"Evaluation of the efficacy and safety of a statin\/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB\/c mice","volume":"38","author":"Liu","year":"2009","journal-title":"Eur J Pharm Sci."},{"key":"B142","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2217\/fvl.12.71","article-title":"Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB\/c mice","volume":"7","author":"Kumaki","year":"2012","journal-title":"Future Virol."},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035788","article-title":"The effect of rosuvastatin in a murine model of influenza A infection","author":"Radigan","year":"2012","journal-title":"PLoS ONE"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1126\/science.309.5743.1976a","article-title":"Infectious disease. Old drugs losing effectiveness against flu; could statins fill gap?","volume":"309","author":"Enserink","year":"2005","journal-title":"Science"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1378\/chest.06-1997","article-title":"Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins","volume":"131","author":"Frost","year":"2007","journal-title":"Chest"},{"key":"B146","first-page":"409","article-title":"Experience in the management of the severe form of human influenza A H1N1 pneumonia in an intensive care unit","volume":"79","author":"Carrillo-Esper","year":"2011","journal-title":"Cir Cir."},{"key":"B147","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/infdis\/jir695","article-title":"Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study","volume":"205","author":"Vandermeer","year":"2012","journal-title":"J Infect Dis."},{"key":"B148","doi-asserted-by":"publisher","first-page":"e8087","DOI":"10.1371\/journal.pone.0008087","article-title":"Influenza morbidity and mortality in elderly patients receiving statins: a cohort study","volume":"4","author":"Kwong","year":"2009","journal-title":"PLoS ONE"},{"key":"B149","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1017\/S0950268810000105","article-title":"An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005-2006","volume":"138","author":"Fleming","year":"2010","journal-title":"Epidemiol Infect."},{"key":"B150","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1475-2891-13-17","article-title":"Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications\u2013a review","volume":"13","author":"Grygiel-Gorniak","year":"2014","journal-title":"Nutr J."},{"key":"B151","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1084\/jem.20080201","article-title":"Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand","volume":"205","author":"Herold","year":"2008","journal-title":"J Exp Med."},{"key":"B152","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1073\/pnas.0900655106","article-title":"TNF\/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection","volume":"106","author":"Aldridge","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B153","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1750-2659.2010.00155.x","article-title":"Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice","volume":"4","author":"Moseley","year":"2010","journal-title":"Influenza Other Respir Viruses"},{"key":"B154","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/infdis\/jir804","article-title":"The prostanoid 15-deoxy-Delta12,14-prostaglandin-j2 reduces lung inflammation and protects mice against lethal influenza infection","volume":"205","author":"Cloutier","year":"2012","journal-title":"J Infect Dis."},{"key":"B155","doi-asserted-by":"publisher","first-page":"5605","DOI":"10.1128\/JVI.00140-10","article-title":"Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors","volume":"84","author":"Bottcher-Friebertshauser","year":"2010","journal-title":"J Virol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1128\/AAC.50.4.1470-1479.2006","article-title":"Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection","volume":"50","author":"Malakhov","year":"2006","journal-title":"Antimicrob Agents Chemother."},{"key":"B157","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/jac\/dkp421","article-title":"DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis","volume":"65","author":"Triana-Baltzer","year":"2010","journal-title":"J Antimicrob Chemother."},{"key":"B158","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/jac\/dkq387","article-title":"Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181","volume":"66","author":"Triana-Baltzer","year":"2011","journal-title":"J Antimicrob Chemother."},{"key":"B159","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1128\/AAC.00389-09","article-title":"DAS181 inhibits H5N1 influenza virus infection of human lung tissues","volume":"53","author":"Chan","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"B160","doi-asserted-by":"publisher","first-page":"e7838","DOI":"10.1371\/journal.pone.0007838","article-title":"Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein","volume":"4","author":"Triana-Baltzer","year":"","journal-title":"PLoS ONE"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007788","article-title":"Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein","author":"Triana-Baltzer","year":"","journal-title":"PLoS ONE"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1086\/522609","article-title":"DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection","volume":"196","author":"Belser","year":"2007","journal-title":"J Infect Dis."},{"key":"B163","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/infdis\/jiu105","article-title":"An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality","volume":"210","author":"Marjuki","year":"2014","journal-title":"J Infect Dis."},{"key":"B164","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.antiviral.2015.09.008","article-title":"Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults","volume":"123","author":"Zenilman","year":"2015","journal-title":"Antiviral Res."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1093\/infdis\/jis622","article-title":"A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection","volume":"206","author":"Moss","year":"2012","journal-title":"J Infect Dis."},{"key":"B166","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.chom.2014.06.005","article-title":"Influenza promotes pneumococcal growth during coinfection by providing host sialylated substrates as a nutrient source","volume":"16","author":"Siegel","year":"2014","journal-title":"Cell Host Microbe"},{"key":"B167","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1086\/651170","article-title":"Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection","volume":"201","author":"Hedlund","year":"2010","journal-title":"J Infect Dis."},{"key":"B168","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/ni875","article-title":"IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex","volume":"4","author":"Kotenko","year":"2003","journal-title":"Nat Immunol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/ni873","article-title":"IL-28, IL-29 and their class II cytokine receptor IL-28R","volume":"4","author":"Sheppard","year":"2003","journal-title":"Nat Immunol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"e1003773","DOI":"10.1371\/journal.ppat.1003773","article-title":"Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia","volume":"9","author":"Crotta","year":"2013","journal-title":"PLoS Pathog."},{"key":"B171","doi-asserted-by":"publisher","first-page":"e1000017","DOI":"10.1371\/journal.ppat.1000017","article-title":"IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo","volume":"4","author":"Sommereyns","year":"2008","journal-title":"PLoS Pathog."},{"key":"B172","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.immuni.2017.04.025","article-title":"Interferon-lambda mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness","volume":"46","author":"Galani","year":"2017","journal-title":"Immunity"},{"key":"B173","doi-asserted-by":"publisher","first-page":"e33354","DOI":"10.7554\/eLife.33354","article-title":"IFN-lambda prevents influenza virus spread from the upper airways to the lungs and limits virus transmission","volume":"7","author":"Klinkhammer","year":"2018","journal-title":"Elife"},{"key":"B174","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1165\/rcmb.2016-0174OC","article-title":"The superiority of IFN-lambda as a therapeutic candidate to control acute influenza viral lung infection","volume":"56","author":"Kim","year":"2017","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.jhep.2014.07.022","article-title":"A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection","volume":"61","author":"Muir","year":"2014","journal-title":"J Hepatol."},{"key":"B176","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.4049\/jimmunol.159.11.5197","article-title":"CD8+ T cells clear influenza virus by perforin or Fas-dependent processes","volume":"159","author":"Topham","year":"1997","journal-title":"J Immunol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/sj.cdd.4400362","article-title":"Co-expression of Fas and Fas-ligand on the surface of influenza virus-infected cells","volume":"5","author":"Fujimoto","year":"1998","journal-title":"Cell Death Differ."},{"key":"B178","doi-asserted-by":"publisher","first-page":"7658","DOI":"10.1128\/JVI.79.12.7658-7663.2005","article-title":"Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice","volume":"79","author":"Ishikawa","year":"2005","journal-title":"J Virol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"4918","DOI":"10.4049\/jimmunol.181.7.4918","article-title":"CD8 T cells utilize TRAIL to control influenza virus infection","volume":"181","author":"Brincks","year":"","journal-title":"J Immunol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.4049\/jimmunol.1002241","article-title":"The magnitude of the T cell response to a clinically significant dose of influenza virus is regulated by TRAIL","volume":"187","author":"Brincks","year":"2011","journal-title":"J Immunol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/nature05181","article-title":"Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus","volume":"443","author":"Kash","year":"2006","journal-title":"Nature"},{"key":"B182","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.humimm.2008.07.012","article-title":"Influenza-induced expression of functional tumor necrosis factor-related apoptosis-inducing ligand on human peripheral blood mononuclear cells","volume":"69","author":"Brincks","year":"","journal-title":"Hum Immunol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"e1003188","DOI":"10.1371\/journal.ppat.1003188","article-title":"Macrophage-expressed IFN-beta contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia","volume":"9","author":"Hogner","year":"2013","journal-title":"PLoS Pathog."},{"key":"B184","doi-asserted-by":"publisher","first-page":"e55321","DOI":"10.1371\/journal.pone.0055321","article-title":"Type-I interferon is critical for FasL expression on lung cells to determine the severity of influenza","volume":"8","author":"Fujikura","year":"2013","journal-title":"PLoS ONE"},{"key":"B185","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/v9080223","article-title":"Influenza virus infection, interferon response, viral counter-response, and apoptosis","volume":"9","author":"Shim","year":"2017","journal-title":"Viruses"},{"key":"B186","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/v9100271","article-title":"Antiviral Properties of chemical inhibitors of cellular anti-apoptotic Bcl-2 proteins","volume":"9","author":"Bulanova","year":"2017","journal-title":"Viruses"},{"key":"B187","doi-asserted-by":"publisher","first-page":"e742","DOI":"10.1038\/cddis.2013.267","article-title":"Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice","volume":"4","author":"Kakkola","year":"2013","journal-title":"Cell Death Dis."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01946\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:44Z","timestamp":1693872044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01946\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,10]]},"references-count":187,"alternative-id":["10.3389\/fimmu.2018.01946"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01946","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,10]]},"article-number":"1946"}}